COVID‐19–Induced Acute Pancreatitis: Clinical Profiles, Outcomes, and Prognostic Indicators From a Global Review‐Based Synthesis

Le résumé fourni par la source

ABSTRACT Background and Aims During the coronavirus disease 2019 (COVID‐19) pandemic, acute pancreatitis (AP) in patients with COVID‐19 has attracted considerable attention. While many reports have described “concurrent COVID‐19 and AP” without excluding established etiologies, the concept of “COVID‐19–induced AP” remains less clearly defined. This study aimed to investigate the associations between initial clinical presentations and outcomes in COVID‐19–induced AP, offering real‐world evidence to identify predictors of short‐term prognosis. Methods This is a review‐based synthesis for human studies, with literature search (October 2019–March 2022) using PubMed dual strategies, “Medical Subject Headings (MeSH)” and “title/abstract.” COVID‐19–induced AP was defined by the exclusion of other established etiologies for pancreatitis. Results We identified 111 patients (median age 39 years) with 11 deaths. Gastrointestinal symptoms preceded admission in 30.6% of cases, while respiratory symptoms preceded admission in 52.3%. Pancreatitis symptoms before admission were associated with younger age, less lymphocyte counts, lower neutrophil‐to‐lymphocyte ratio, and higher radiologic severity (Balthazar score). Initial white blood cell (WBC) count ≥ 14,000/µL and pancreatic necrosis correlated with surgical intervention. Kaplan–Meier analysis demonstrated that overall survival was not influenced by the sequence of gastrointestinal and respiratory symptom onset (concurrent vs. successive; p = 0.543) or by whether pancreatitis symptoms developed before or after hospital admission ( p = 0.228). Multivariate Cox regression identified elevated WBC count (hazard ratio [HR]: 1.013; 95% confidence interval [CI]: 1.000–1.025; p = 0.042), AST‐to‐ALT ratio ≥ 2 (HR: 11.052; 95% CI: 1.441–84.770; p = 0.021), and surgical intervention (HR: 6.604; 95% CI: 1.581–27.593; p = 0.010) as independent mortality predictors. Conclusion Unlike “concurrent COVID‐19 and AP (without excluding established AP etiologies),” “COVID‐19–induced AP” showed no survival disparity by symptom chronology. Mortality was linked to leukocytosis, AST‐to‐ALT ratio, and surgical intervention. Standardized terminology distinguishing “COVID‐19–induced AP” from “concurrent COVID‐19 and AP” is essential to ensure comparability of global clinical data and reduce interpretive bias.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.